Holen Sie sich die Stockscreener-App
123.29
3.05%
-3.79
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$127.08
Offen:
$125.77
24-Stunden-Volumen:
463.73K
Relative Volume:
0.31
Marktkapitalisierung:
$13.76B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$239.11M
KGV:
58.44
EPS:
2.1097
Netto-Cashflow:
$492.62M
1W Leistung:
-5.91%
1M Leistung:
+7.45%
6M Leistung:
+33.76%
1J Leistung:
+44.88%
1-Tages-Spanne:
$121.20
$126.66
1-Wochen-Bereich:
$121.20
$133.00
52-Wochen-Spanne:
$81.22
$133.00
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, NTRA, IQV, IDXX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
123.28 | 14.18B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
606.27 | 222.97B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
205.02 | 144.27B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.84 | 46.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
255.63 | 42.67B | 16.63B | 1.39B | 2.12B | 8.0674 |
IDXX
Idexx Laboratories Inc
|
520.34 | 40.98B | 4.45B | 1.10B | 1.06B | 13.59 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Goldman | Neutral |
| 2025-10-16 | Eingeleitet | Guggenheim | Neutral |
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
RVTY Assumes Rating by UBS -- Price Target Raised to $140 - GuruFocus
Revvity Acquiring French Firm Human Cell Design - GenomeWeb
Revvity at Wells Fargo 21st annual healthcare conference: growth and margin focus - Investing.com Canada
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition - Benzinga
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery - BioSpace
RVTY Looks 8.1% Overvalued on GF Value™ - GuruFocus
RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow - GuruFocus
Revvity to Acquire Human Cell Design - marketscreener.com
Revvity to acquire Human Cell Design - TradingView
Revvity to acquire Human Cell Design for metabolic research tools - Investing.com
Revvity to acquire Human Cell Design for metabolic research tools By Investing.com - Investing.com Canada
A planned Revvity deal would add human pancreatic cells for diabetes research - Stock Titan
Revvity Inc. stock slips despite solid Q2 2026 growth and cautious analyst outlook - AD HOC NEWS
Revvity stock heads into the open after a 2.1 percent drop - AD HOC NEWS
Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
T. Rowe Price controls over 10M Revvity (NYSE: RVTY) shares, with one fund holding about half the stake - Stock Titan
Revvity Inc. stock holds above 130 dollars as analysts stick with Hold ratings - AD HOC NEWS
Revvity, Inc. (RVTY) Stock Analysis: Navigating Potential in the Diagnostics Sector Amid Mixed Ratings - DirectorsTalk Interviews
KeyBanc Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich? - Eastern Progress
KeyBanc Adjusts Price Target on Revvity to $165 From $125, Maintains Overweight Rating - marketscreener.com
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Revvity Inc. stock holds near 52-week high as valuation debate intensifies - AD HOC NEWS
Baird Adjusts Price Target on Revvity to $144 From $131, Keeps Outperform Rating - marketscreener.com
Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings - Yahoo Finance
Revvity Inc (RVTY) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 77/100 - GuruFocus
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade - Yahoo Finance
What Makes Revvity (RVTY) a New Buy Stock - Yahoo Finance
Revvity Faces Growth Challenges Amid Rising Competition, RBC Says - marketscreener.com
RBC Initiates Revvity at Sector Perform With $135 Price Target - marketscreener.com
RBC Capital initiates Revvity stock with Sector Perform rating By Investing.com - Investing.com Australia
RBC Capital initiates Revvity stock with Sector Perform rating - Investing.com
Revvity, Inc. (RVTY) Stock Analysis: Navigating a 6% Potential Downside with Strategic Insights - DirectorsTalk Interviews
Revvity (RVTY) Eases to $128.8: Key Support at $122.36 Holds in FocusImbalance Zone - vinanet.vn
Revvity Inc stock hits 52-week high at 130.07 USD By Investing.com - Investing.com Nigeria
Revvity Inc stock hits 52-week high at 130.07 USD - Investing.com
Revvity (NYSE: RVTY) director donates 285 shares in stock gift - Stock Titan
Revvity, Inc. (RVTY) Stock Analysis: Healthcare Innovator With Mixed Growth Signals - DirectorsTalk Interviews
Revvity stock trades around $123 as investors weigh latest earnings and analyst targets - Ad-hoc-news.de
Why Revvity (RVTY) Stock Is Up Today - Quiver Quantitative
Revvity stock hits new 52-week high as gains extend - Ad-hoc-news.de
Revvity stock hits 52-week high at 122.26 USD - Investing.com
Revvity stock hits 52-week high at 122.26 USD By Investing.com - Investing.com India
Revvity Inc (RVTY) Shares Surge 5.0% -- What GF Score of 78 Tells Investors - GuruFocus
Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Revvity stock edges lower as SuperFlex launch and Q2 earnings shape valuation debate - Ad-hoc-news.de
Revvity Inc (RVTY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revvity (NYSE: RVTY) executive gifts 27,785 shares to trust - Stock Titan
Revvity (NYSE:RVTY) Gains Attention After SuperFlex Launch - Kalkine Media
Revvity CEO Prahlad Singh Transfers Over 67,000 Shares to Family Trusts in Gift Transactions - Kalkine Media
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
1.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):